Drug Trial Radar · NCT07915921
A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Nov 15, 2026
Primary completion
Apr 30, 2028
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- Genfleet Therapeutics (Shanghai) Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib/II study to explore the safety/tolerability, efficacy, and pharmacokinetic (PK) characteristics of GFH276 in combination with chemotherapy (+/- bevacizumab) or cetuximab in patients with RAS-mutant metastatic colorectal cancer (mCRC).
Conditions
- CRC
Interventions
IrinotecanDrug
Intravenous irinotecan at a dose of 150 mg/m?
OxaliplatinDrug
Intravenous oxaliplatin at a dose of 85 mg/mr
GFH276Drug
Oral GFH276 administered once daily in combination with other study drugs.
Fluorouracil (5-FU)Drug
Intravenous Fluorouracil at a dose of 2400 mg/m2 via 46-hour infusion.
LeucovorinDrug
Intravenous leucovorin at a dose of 400 mg/m
BevacizumabDrug
at a dose of 5mg/kg
Cetuximab (CRC)Drug
at a dose of500 mg/㎡
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Incidence and severity of AEs and SAEsTime frame: up to 24 months
- Phase Ib: The incidence of DLT events: The incidence of DLT eventsTime frame: First 28 days
- Phase II: Objective response rate (ORR)Time frame: From first use of medication to disease progression,up to 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.